Singh Vijay Brown Darren Kao (1 results)

Stapled at upper left corner. Condition: Good. Pages 61-70. Illustrations. There are six black and white graphs showing results post radiation. Minor highlighting on front page. Topics covered include Materials and Methods, Results, and References. Dr. Singh was with the Radiation Countermeasures Program and the Department of Radiation Biology at the Armed Forces Radiobiology Research Institute. Dr. Brown was also with that Department. Dr. Kao was with the Uniformed Services University of the Health Sciences. Dr. Singh's primary research interests are to develop radiation countermeasures for acute radiation syndrome (ARS). My activities for this endeavor can be divided into the following major categories: 1) Development of genistein (isoflavone - BIO 300/BIO 301) as radiation countermeasure for ARS and delayed effects of acute radiation exposure (DEARE), 2) Identification and validation of biomarkers for radiation injury and countermeasure efficacy,and 3) Advanced development of promising radiation countermeasures such as tocols, Ex-RAD, myeloid progenitors, anticeramide-antibody and other related agents. His laboratory has extensive experience in studying the effects of various radiation countermeasures on injury and recovery. His research objective is to identify and validate non-invasive biomarkers for radiation injury and countermeasure efficacy. His laboratory has identified and validated several biomarkers for radiation dose assessment and efficacy of radiation countermeasures using various omic platforms. He is the recipient of several prestigious award and serves as editorial board member for several reputed journals. This paper addressed victims of a terrorism attack presenting with the hematopoietic syndrome resulting from exposure to excessive levels of ionizing radiation will succumb to sepsis if not adequately treated. The probability of survival is increased substantially if the victim's immune system is allowed to recover before sepsis sets in. The authors report on preclinical development of a new bridging therapy that will allow victims of radiation casualties to recover from damage caused by ionizing radiation. Experimental Hematology? publishes original research reports (regular and fast-track submissions), reviews, letters to the editor, and abstracts of the annual meeting of ISEH - International Society for Experimental Hematology. We welcome manuscripts describing basic in vitro and in vivo research centered on normal and malignant hematopoiesis as well as non-malignant hematologic diseases. Submissions focused on non-hematopoietic stem cells (e.g. mesenchymal stem cells, embryonic stem cells and induced pluripotent stems) with potential relevance to hematopoiesis are also welcome, as are studies involving experimental or early phase clinical cell transplantation. Studies employing genomic and systems biology approaches to the study of normal and malignant hematopoiesis are strongly encouraged, as are those employing model organisms. Xerox style copy of offprint from the Society for Hematology and Stem Cells journal Experimental Hematology 2010;38;61-70.